Clinical Trial Update: 52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine [Phase 3]

View source ↗

Summary

This Phase 3 randomized trial compared lumiracoxib 100 mg once daily and lumiracoxib 100 mg twice daily with celecoxib 200 mg once daily in adults with osteoart…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Celecoxib (Celecoxib)
• Lumiracoxib (Lumiracoxib)

Snippet

Sponsor: Novartis | Conditions: Osteoarthritis | Phase 3 | Status: COMPLETED